Opus Genetics Inc (IRD)

$1.88 +0.08 (4.44%)
Market Cap 112.63M
Revenue (ttm) 10.99M
Net Income (ttm) -57.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -523.48%
Debt to Equity Ratio 0.06
Volume 344,200
Avg Vol 267,586
Day's Range N/A - N/A
Shares Out 59.91M
Stochastic %K 90%
Beta 0.11
Analysts Strong Sell
Price Target $6.67

Company Profile

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal do...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
SilentFills
SilentFills Oct. 5 at 8:12 AM
$IRD Financial services niche. No technical pattern. Illiquid conditions. Better opportunities elsewhere.
0 · Reply
ThomasJerryLLC
ThomasJerryLLC Oct. 4 at 4:00 AM
$IRD 6 month chart looks strong. Quiet accumulation, buyers in control, easily absorbing selling pressure. Seems like solid conviction from buyers. these can happen this year: *OPGx-BEST1, phase 1/2 trial start *phentolamine (for presbyopia) sNDA filing (possibly mid/late Oct 2025) *FDA accepts sNDA for review (mid/late Dec 2025 )📈 *phentolamine (for night vision), LYNX-3 phase 3 start *OPGx-LCA5, FDA meeting on pivotal trial design
0 · Reply
RCO234
RCO234 Oct. 3 at 8:26 PM
$IRD This is one of the most solid set ups I’ve seen in a while. Anything can happen but this company seems to have a solid base and good news
0 · Reply
retro123
retro123 Oct. 3 at 4:26 PM
$IRD cant wait for the next leg up
0 · Reply
TruthTooPower
TruthTooPower Oct. 2 at 1:18 PM
$IRD!!! Zack Under $20 B/O $DRMA !!! 498k Float Monsters Not Waiting For Halloween!!!
0 · Reply
JussieLivermore
JussieLivermore Oct. 1 at 10:58 PM
$IRD Nice to see it move quickly back above $1.75, inside green day, if we take out today's high and stay above could see the start of the next leg up.
0 · Reply
Um8a123
Um8a123 Oct. 1 at 7:29 PM
$IRD Moved my limit sell to 10 bucks.
0 · Reply
JussieLivermore
JussieLivermore Sep. 30 at 6:19 PM
$IRD 6 out of 6 patients have experienced a meaningful improvement. Increases probability of BEST1 success. Analyst on call had favorable comments. Company is executing well across many programs.
1 · Reply
Bakhmutbull2
Bakhmutbull2 Sep. 30 at 2:59 PM
$IRD lil jenny says yellow looks yellower...stopped out..good luck
0 · Reply
Atime2Buy
Atime2Buy Sep. 30 at 2:46 PM
$IRD love this stock ….. every time it gets positive news it drops like rock.
0 · Reply
Latest News on IRD
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Oct 2, 2025, 8:00 AM EDT - 2 days ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Opus Genetics, Inc. - Special Call

Sep 30, 2025, 12:12 PM EDT - 4 days ago

Opus Genetics, Inc. - Special Call

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Sep 30, 2025, 7:00 AM EDT - 4 days ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2025, 8:00 AM EDT - 22 days ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 4, 2025, 8:00 AM EDT - 4 weeks ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 4 weeks ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Sep 2, 2025, 8:00 AM EDT - 4 weeks ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 27, 2025, 8:00 AM EDT - 5 weeks ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 18, 2025, 8:00 AM EDT - 6 weeks ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 7 weeks ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 5, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 23, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 4:30 PM EDT - 3 months ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 26, 2025, 6:55 AM EDT - 3 months ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Jun 23, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 11, 2025, 3:47 PM EDT - 6 months ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 8, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics to Participate in Upcoming Investor Conference in April

Apr 2, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Opus Genetics Announces Financial Results for Full Year 2024

Mar 31, 2025, 8:20 AM EDT - 6 months ago

Opus Genetics Announces Financial Results for Full Year 2024

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 5:03 PM EDT - 7 months ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:30 AM EDT - 7 months ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 21, 2025, 9:11 AM EDT - 7 months ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 5, 2025, 8:00 AM EST - 7 months ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 26, 2025, 8:00 AM EST - 7 months ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 18, 2025, 7:30 AM EST - 8 months ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Feb 7, 2025, 9:15 AM EST - 8 months ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Dec 19, 2024, 8:00 AM EST - 10 months ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

SilentFills
SilentFills Oct. 5 at 8:12 AM
$IRD Financial services niche. No technical pattern. Illiquid conditions. Better opportunities elsewhere.
0 · Reply
ThomasJerryLLC
ThomasJerryLLC Oct. 4 at 4:00 AM
$IRD 6 month chart looks strong. Quiet accumulation, buyers in control, easily absorbing selling pressure. Seems like solid conviction from buyers. these can happen this year: *OPGx-BEST1, phase 1/2 trial start *phentolamine (for presbyopia) sNDA filing (possibly mid/late Oct 2025) *FDA accepts sNDA for review (mid/late Dec 2025 )📈 *phentolamine (for night vision), LYNX-3 phase 3 start *OPGx-LCA5, FDA meeting on pivotal trial design
0 · Reply
RCO234
RCO234 Oct. 3 at 8:26 PM
$IRD This is one of the most solid set ups I’ve seen in a while. Anything can happen but this company seems to have a solid base and good news
0 · Reply
retro123
retro123 Oct. 3 at 4:26 PM
$IRD cant wait for the next leg up
0 · Reply
TruthTooPower
TruthTooPower Oct. 2 at 1:18 PM
$IRD!!! Zack Under $20 B/O $DRMA !!! 498k Float Monsters Not Waiting For Halloween!!!
0 · Reply
JussieLivermore
JussieLivermore Oct. 1 at 10:58 PM
$IRD Nice to see it move quickly back above $1.75, inside green day, if we take out today's high and stay above could see the start of the next leg up.
0 · Reply
Um8a123
Um8a123 Oct. 1 at 7:29 PM
$IRD Moved my limit sell to 10 bucks.
0 · Reply
JussieLivermore
JussieLivermore Sep. 30 at 6:19 PM
$IRD 6 out of 6 patients have experienced a meaningful improvement. Increases probability of BEST1 success. Analyst on call had favorable comments. Company is executing well across many programs.
1 · Reply
Bakhmutbull2
Bakhmutbull2 Sep. 30 at 2:59 PM
$IRD lil jenny says yellow looks yellower...stopped out..good luck
0 · Reply
Atime2Buy
Atime2Buy Sep. 30 at 2:46 PM
$IRD love this stock ….. every time it gets positive news it drops like rock.
0 · Reply
TheAliAbdul
TheAliAbdul Sep. 30 at 2:40 PM
$IRD 5% down on positve news?
0 · Reply
Rachel20201
Rachel20201 Sep. 30 at 1:37 PM
$IRD Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
0 · Reply
whyyoucare
whyyoucare Sep. 30 at 1:01 PM
$IRD when are all the bot accounts that spam news everywhere going to start posting.....let's get some volume and eyes here! https://finance.yahoo.com/news/opus-genetics-reports-positive-pediatric-110000885.html
0 · Reply
yft212
yft212 Sep. 30 at 12:39 PM
$IRD https://ir.opusgtx.com/press-releases/detail/501/opus-genetics-reports-positive-pediatric-data-from-opgx-lca5-phase-12-trial-in-leber-congenital-amaurosis-type-5-lca5
0 · Reply
bondia
bondia Sep. 30 at 12:08 PM
$IRD good morning like jussie told before ;-) Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) https://finance.yahoo.com/news/opus-genetics-reports-positive-pediatric-110000885.html
1 · Reply
TruthTooPower
TruthTooPower Sep. 29 at 4:05 PM
$IRD!!! $SPRU!!! Now We Start The Mid-Day Run Up!! Rock-On!!!
0 · Reply
Maynard_Keysian
Maynard_Keysian Sep. 28 at 10:03 PM
$IRD With the gene therapy already proven effective in adults (Positive 12-month adult data reported), I would think the the odds of the pediatric study to be higher than historical averages. Agree with others, expect results are imminent.
1 · Reply
bondia
bondia Sep. 27 at 3:09 AM
$IRD
1 · Reply
ThomasJerryLLC
ThomasJerryLLC Sep. 27 at 2:20 AM
$IRD without a near term catalyst, high PE and institutional ownership can raise downside risk. But with a Ph 1/2 readout, it looks bullish. Investors are positioned to boost upside. Whales with life science divisions know how big Ph 1/2 and Ph 2 readouts really are 🐋✌️
1 · Reply
Novice1a
Novice1a Sep. 26 at 9:48 PM
$IRD 1.5 million https://ir.stockpr.com/opusgtx/sec-filings-email/content/0001140361-25-036321/ef20055971_s8.htm
0 · Reply
wvytee
wvytee Sep. 26 at 7:55 PM
$IRD this moving like rytm when was at 3ish
0 · Reply
JussieLivermore
JussieLivermore Sep. 26 at 7:25 PM
$IRD Not many business days left for the company to hit its expected timeline for OPGx-LCA5 pediatric data. I would be surprised if they miss the date, they have had several recent presentations showing that date. Come Monday?
0 · Reply